Trial site
Fondazione Luigi Maria Monti
Rome, 00167, ItalyNot linked to an institution yet
- 13running trials
- 7closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 24 trials
- Phase 2/33 trials
- Phase 1/22 trials
- Phase 11 trial
- Status
- Active, not recruiting9 trials
- Completed6 trials
- Not yet recruiting2 trials
- Recruiting2 trials
- Withdrawn1 trial
- Lead sponsor
- Amgen Inc.2 trials
- Boehringer Ingelheim2 trials
- Regeneron Pharmaceuticals2 trials
- Ascendis Pharma Oncology Division A/S1 trial
- Erasca, Inc.1 trial
- and 12 more
Running trials
Recruiting
A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients with Epidermolysis Bullosa
2024-515172-12-00· Phase 2· Xinnate AB· Source
Not yet recruiting
“A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo”
2025-523266-24-00· Phase 2· I.F.O. Istituti Fisioterapici Ospitalieri· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811· Phase 3· Incyte Corporation· Source
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917· Phase 2· Sanofi· Source
Active, not recruiting
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283· Phase 2· Takeda· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· Phase 3· Erasca, Inc.· Source
Active, not recruiting
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
NCT06073132· Phase 2/3· TWi Biotechnology, Inc.· Source
Active, not recruiting
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma
2023-503288-40-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· Phase 3· HUYABIO International, LLC.· Source
Not yet recruiting
NEurotrophins Mimetic compound for the treatment of diabetic foot UlcerS
2024-519405-35-00· Phase 1/2· Mimetech S.r.l.· Source
Active, not recruiting
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03553836· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error